The HRH1 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population derived from the HeLa cell line, designed to disrupt the HRH1 gene encoding the histamine H1 receptor. This product is supplied as a heterogeneous pool of cells bearing targeted gene disruptions, enabling loss-of-function studies without clonal selection. The polyclonal format retains population-level diversity while abrogating HRH1-dependent signaling, providing a robust model for investigating receptor-mediated pathways in a widely used human cellular background. Researchers can utilize these cells to dissect HRH1-specific contributions to signal transduction, gene expression, and phenotypic responses in a consistent genetic context.
HeLa cells, an immortalized line originating from human cervical adenocarcinoma, serve as a fundamental platform in biomedical research owing to their robust growth and well-characterized biology. As epithelial cells derived from a malignant tissue, HeLa cells retain key features of cervical cancer, including active proliferation and signaling networks relevant to tumorigenesis and inflammation. Their extensive use in drug discovery and molecular biology makes them an ideal host for generating a targeted knockout model of HRH1, facilitating comparative analyses between wild-type and receptor-deficient states across a range of experimental conditions.
HRH1 encodes the histamine H1 receptor, a Gq/11-coupled receptor that mediates critical allergic and inflammatory responses. Upon binding its primary ligand histamine, HRH1 activates the heterotrimeric G proteins GNAQ and GNA11, leading to phospholipase C beta (PLCB1/2) stimulation, hydrolysis of phosphatidylinositol 4,5-bisphosphate, and generation of the second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes intracellular calcium stores, while DAG activates protein kinase C (PRKCA, PRKCB). Downstream, calcium/calmodulin (CALM1) and PKC converge on NF-kB (NFKB1), promoting transcription of pro-inflammatory genes. The signaling cascade is tightly regulated by upstream modulators such as histidine decarboxylase and diamino oxidase, and desensitized by G protein-coupled receptor kinases (GRK2) and arrestins (ARRB1, ARRB2).
Disruption of HRH1 in HeLa cells offers a physiologically relevant system to explore histamine-driven signaling in an epithelial cancer model. HeLa cells endogenously express components of the Gq/11-PLC pathway, making them permissive for studying HRH1-dependent calcium fluxes, transcriptional responses, and cytokine production. This knockout model is particularly valuable for investigating the intersection of allergic inflammation and cervical adenocarcinoma biology, where histamine may influence tumour microenvironment dynamics. It also enables dissection of HRH1-specific contributions versus other histamine receptor subtypes, such as HRH2 or HRH4, in modulating cellular outcomes like proliferation, migration, or apoptosis.
These polyclonal knockout cells are suited for a variety of research applications in allergy, inflammation, and receptor pharmacology. They can be employed in calcium mobilization assays to directly assess histamine-induced intracellular calcium release, phospho-signaling analyses (e.g., phospho-PKC or phospho-NF-kB) to map pathway activation, and NF-kB reporter assays to quantify transcriptional output. Additional techniques include RT-qPCR for gene expression profiling, western blotting for protein-level validation, immunofluorescence for receptor localization studies, and flow cytometry for phenotypic characterization. The knockout model also supports antihistamine drug screening and structure-activity relationship studies targeting the H1 receptor. For further details, please contact Ascent Research.
